Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 651 - 675 of 817 in total

Amrubicin

Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January...
Investigational

Nicotinamide adenine dinucleotide cyclohexanone

Experimental

4-hydroxyphenacyl coenzyme A

Experimental

(S)-4-bromo-3-hydroxy-3-methylbutyl diphosphate

Experimental

6-phospho-D-gluconic acid

Experimental

{1-[(3-Hydroxy-Methyl-5-Phosphonooxy-Methyl-Pyridin-4-Ylmethyl)-Amino]-Ethyl}-Phosphonic Acid

Experimental

8-demethyl-8-dimethylamino-flavin-adenine-dinucleotide

Experimental

Thionicotinamide-Adenine-Dinucleotide

Experimental

2-Dimethylamino-Ethyl-Diphosphate

Experimental

Nitromethyldethia coenzyme A

Experimental

4-phospho-D-erythronic acid

Experimental

PAS219

Experimental

Nicotinamide adenine dinucleotide 3-pentanone adduct

Experimental

Methacrylyl-Coenzyme A

Experimental

Propanoyl-CoA

Experimental

CoA-s-acetyl tryptamine

Experimental

3-Hydroxybutyryl-Coenzyme A

Experimental

6-hydroxy-FAD

Experimental

GDP-alpha-D-mannuronic acid

Experimental

Cpad

Experimental

Adenylosuccinic acid

Experimental

P1-(5'-Adenosyl)P5-(5'-(3'azido-3'-Deoxythymidyl))Pentaphosphate

Experimental

CTT-1057

CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).
Investigational

Canfosfamide

Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
Investigational

2'-fluoro-2'-deoxyuridine 3'-monophosphate

Experimental
Displaying drugs 651 - 675 of 817 in total